Golimumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), NICE (England) and TLV (Sweden) recommended or restricted golimumab, while AOTMIT (Poland) and AWMSG (Wales) did not recommend it.
The file has been open for more than a decade: 17.2 years separate the first record, 16 Jan 2009 at AWMSG (Wales), from the most recent, 28 Apr 2026 at TLV (Sweden).
NICE (England) changed its position: restricted on 27 Apr 2011, recommended by 10 Jan 2018.
No assessment is on file from G-BA (Germany), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for golimumab, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 3 of 43 records date from 2023 or later.
The programme is broad: 17 distinct indication wordings are recorded for golimumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 43 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess golimumab, on 16 Jan 2009; CIPM (Spain) did not open a file until 17 Dec 2025 — an unusually long tail of 16.9 years between the earliest and latest system to look at it.
The record arrives in waves: 10 separate years each carry two or more decisions, spread across 14 years in total.
8 of the 10 agencies here assessed golimumab more than once, AWMSG (Wales) most often at 8 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for golimumab.
The full ledger for golimumab reads 15 recommended, 13 not recommended, 7 restricted and 4 deferred to NICE, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| TLV (Sweden) | 27 Jan 2026 | Gobivaz ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| CIPM (Spain) | 17 Dec 2025 | SECRETARIA DE ESTADO DE SANIDAD 13 MINISTERIO DE SANIDAD MINISTERIO DE SANIDAD Indicaciones terapéuticas autorizadas: Ar… | financed by the SNS · art. 92 e | source |
| CONITEC (Brazil) | 15 Mar 2022 | Tratamento de pacientes adultos com retocolite ulcerativa moderada a grave, com resposta inadequada ou intolerantes às t… | not incorporated | source |
| HAS (France) | 6 Oct 2021 | Re-assessment following post-listing study results | SMR substantial | source |
| AWMSG (Wales) | 5 Oct 2016 | Treatment of adults with severe, active non radiographic axial spondyloarthritis (nr-axSpA) with objective signs of infl… | superseded (full) | source |
38 further decisions for golimumab, across 9 agencies, are not shown here. They include the most recent record on file, 28 Apr 2026 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 25 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 43 decisions for golimumab from 10 agencies, 2009 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.